Format

Send to

Choose Destination
Semergen. 2016 Oct;42(7):464-475. doi: 10.1016/j.semerg.2016.07.009. Epub 2016 Sep 15.

[Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevención].

[Article in Spanish]

Author information

1
Médico de Familia, Coordinadora del Grupo de Actividades Preventivas y Salud Pública SEMERGEN, Centro de Salud Internacional Madrid Salud, Ayuntamiento de Madrid, Madrid, España. Electronic address: redondome@madrid.es.
2
Pediatra, Departamento de Pediatría Clínica, Infectológica y Traslacional, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, España; Genética, Vacunas, Infecciones y Pediatría (GENVIP), Instituto de Investigación de Santiago, Santiago de Compostela, A Coruña, España.
3
Médico de Familia, Unidad de Hospitalización Versátil, Hospital de Alta Resolución El Toyo, Agencia Pública Sanitaria, Hospital de Poniente, Almería, España.
4
Médico de Familia, Departamento de Salud Dr. Peset, Centro de Atención Primaria Fuente de San Luís, Valencia, España.
5
Médico de Familia, Centro de Atención Primaria de Guadalajara, Guadalajara, España.
6
Médico de Familia y microbiólogo clínico, Miembro del Grupo de Enfermedades Infecciosas de SEMERGEN, Fundación io, Madrid, España.
7
Médico de Familia, Centro de Salud Actur Sur, Zaragoza, España.
8
Especialista en Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, España.
9
Médico de Familia, Centro de Atención Primaria Francia, Fuenlabrada, Madrid, España.
10
Médico de Familia, Responsable Grupo de Trabajo Vacunas SEMG, Centro de Salud Isla de Oza, Madrid, España.
11
Médico de Familia, Miembro del Grupo de Respiratorio SEMG, Centro de Salud Algeciras Norte, Algeciras, Cádiz, España.

Abstract

INTRODUCTION:

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in adults. The annual incidence of CAP in adults in Spain ranges from 3 to 14 cases per 1,000 inhabitants. Current clinical guidelines primarily focus on the therapeutic approach to CAP rather than its prevention. The aim of this study is to develop and propose a practical guide for CAP prevention through vaccination in Spain according to available vaccines and evidence.

METHODS:

A literature review and expert opinion.

RESULTS:

Pneumococcal and influenza vaccines are the main preventive tools available against CAP. Age, chronic diseases, and immunosuppression are risk factors for pneumonia, so these populations should be a priority for vaccination. In addition, influenza and pneumococcal vaccination is considered advisable in healthy adults under 60 years of age, and anyone with risk condition for CAP, irrespective of age. The influenza vaccine will be administered seasonally, while pneumococcal vaccination can be administered at any time of the year.

CONCLUSIONS:

Vaccination against pneumococcus and influenza in adults can help to reduce the burden of CAP and its associated complications. The available evidence supports the priority indications set out in this guide, and it would be advisable to try to achieve a wide circulation and practical implementation of these recommendations.

KEYWORDS:

Community-acquired pneumonia; Flu vaccination, Pneumococcal conjugate vaccine, Pneumococcal Polysaccharide Vaccine; Neumonía adquirida en la comunidad; Vacuna antineumocócica conjugada; Vacuna antineumocócica polisacárida; Vacunación antigripal

PMID:
27641310
DOI:
10.1016/j.semerg.2016.07.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center